🧈 Hypertriglyceridemia Management
This tool directs hypertriglyceridemia management by triglyceride level and ASCVD risk, distinguishing pancreatitis prevention in severe disease from cardiovascular risk reduction in mild-moderate disease.
Hypertriglyceridemia Management
Triglyceride level
ASCVD or high diabetes risk
When to use
Use to choose the main line: severe TG (≥ 500 mg/dL) prioritizes a fibrate and very-low-fat diet to prevent pancreatitis, while mild-moderate TG is lifestyle-led with a statin and possible icosapent ethyl.
How it works
Severe (≥ 500 mg/dL) → fibrate + very-low-fat diet + treat secondary causes (± ω-3), statin only after TG < 500. Mild-moderate (150–499) → lifestyle + statin by risk; high-risk on statin with TG ≥ 150 → add icosapent ethyl.
Key points
- In severe hypertriglyceridemia the goal is preventing acute pancreatitis, so a fibrate (not a statin alone) leads, alongside a very-low-fat diet and secondary-cause treatment. (original synthesis · not guideline verbatim)
- Icosapent ethyl (REDUCE-IT) lowers major cardiovascular events ~25% in high-risk patients with persistent TG ≥ 150 on a statin.
- Uncontrolled diabetes, hypothyroidism, alcohol, and certain drugs are common secondary drivers worth correcting first.
References
- Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation 2019.
- Virani SS, et al. 2021 ACC Expert Consensus Decision Pathway on Hypertriglyceridemia. J Am Coll Cardiol 2021.
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.